Ignet

Gene Information

Gene symbol: PRKAR1A

Gene name: protein kinase, cAMP-dependent, regulatory, type I, alpha

HGNC ID: 9388

Related Genes

#	Gene Symbol	Number of hits
1	IFNG	1 hits
2	RPS27A	1 hits
3	SP1	1 hits
4	TNF	1 hits

Related Sentences

#	PMID	Sentence
1	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
2	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
3	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
4	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
5	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
6	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
7	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
8	24478392	Synergistic effect of interferon-gamma and tumor necrosis factor-alpha on coxsackievirus and adenovirus receptor expression: an explanation of cell sloughing during testicular inflammation in mice.
9	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
10	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
11	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
12	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
13	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
14	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
15	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
16	24478392	Interferon-gamma (IFNG) and tumor necrosis factor alpha (TNF) are two major cytokines that are elevated during testicular inflammation and cause reduced fertility.
17	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
18	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
19	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
20	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
21	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
22	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
23	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
24	24478392	We investigated the mechanism by which IFNG and TNF exert their disruptive effects on testicular cell adhesion.
25	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
26	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
27	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
28	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
29	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
30	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
31	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
32	24478392	We have demonstrated that combined treatment with IFNG and TNF (IFNG+TNF) exerts a synergistic effect by downregulating CAR mRNA and protein levels.
33	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
34	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
35	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
36	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
37	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
38	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
39	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
40	24478392	Immunofluorescence staining revealed that IFNG+TNF treatment effectively removes CAR from the site of cell-cell contact.
41	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
42	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
43	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
44	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
45	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
46	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
47	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
48	24478392	Using inhibitor and co-immunoprecipitation, we confirmed that IFNG+TNF mediates CAR protein degradation via ubiquitin-proteasome and NFKB pathways.
49	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
50	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
51	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
52	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
53	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
54	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
55	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
56	24478392	Blockage of ubiquitin-proteasome pathway significantly inhibits CAR degradation, as indicated by the reappearance of CAR at the site of cell-cell contact.
57	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
58	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
59	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
60	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
61	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
62	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
63	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
64	24478392	Additionally, IFNG+TNF reduces CAR mRNA via transcriptional regulation.
65	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
66	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
67	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
68	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
69	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
70	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
71	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
72	24478392	Mutational studies have shown that IFNG+TNF-induced CAR repression is achieved by suppression of the basal transcription.
73	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
74	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
75	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
76	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
77	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
78	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
79	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
80	24478392	Electrophoretic mobility shift assay and chromatin immunoprecipitation assays further confirmed that IFNG+TNF treament not only inhibits binding of the basal transcription factors but also promotes binding of NFKB subunits and Sp1 (negative regulators) to the CAR promoter region.
81	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
82	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
83	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
84	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
85	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
86	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
87	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.
88	24478392	Taken together, IFNG+TNF treatment significantly downregulates CAR expression, which provides an explanation of how cell sloughing in the epithelium mediates, by loss of CAR-based cell adhesion, during testicular inflammation.